A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult

Authors

  • Dr. Kanishk Yadav
  • Dr. Sachin Kuchya
  • Dr. Akshata Kalyani

DOI:

https://doi.org/10.32677/ijcr.v8i3.3317

Keywords:

Spondyloarthritis, Tumor necrosis factor-α inhibitor, Infliximab, Adalimumab

Abstract

Therapeutic options for patients with Spondyloarthritis (SpA) are limited. The present-day pharmacotherapy for Spondyloarthritis comprises immunomodulator/suppressive drugs. In this case report, we describe a 29-year old Postgraduate resident in Medicine who was diagnosed with spondyloarthritis and was managed by a combination of various disease-modifying drugs like methotrexate and sulfasalazine and immunomodulators such as systemic corticosteroids as well as Tumor Necrosis Factor-alfa inhibitors. After a series of therapeutic trials with them, the chimeric TNF blocker Infliximab led to significant clinical improvement in symptoms and reduction in disease activity.

Downloads

Download data is not yet available.

Downloads

Published

2022-03-27

Issue

Section

Case Report

How to Cite

A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult. (2022). Indian Journal of Case Reports, 8(3), 58-61. https://doi.org/10.32677/ijcr.v8i3.3317

Most read articles by the same author(s)

<< < 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 > >>